Form 4: Astera Labs CFO Sells Shares, Transfers to Trust
Insider Transaction Report
Astera Labs' CFO, Michael Truett Tate, sold shares to cover tax obligations and transferred a significant block of shares to a family trust.
Summary
- Michael Truett Tate, Chief Financial Officer of Astera Labs, Inc. (ALAB), engaged in multiple transactions involving the company's common stock.
- On August 18, 2025, Tate sold 9,668 shares at a weighted average price of $183.8343 and an additional 9,193 shares at a weighted average price of $183.1692.
- These sales, totaling 18,861 shares, were non-discretionary 'sell to cover' transactions, mandated to satisfy tax withholding obligations in connection with the vesting and settlement of previously granted restricted stock units.
- On August 19, 2025, Tate transferred 55,785 shares of common stock to the Tate 1997 Living Trust Dated April 24, 1997 for no consideration.
- Following these reported transactions, Tate directly holds 203,727 shares, and the Tate Trust indirectly holds 457,281 shares.
Sentiment
Score: 5
Explanation: The transactions are routine for an executive, involving non-discretionary 'sell to cover' for tax purposes and a gift to a trust for estate planning. They do not indicate a change in management's confidence or company performance.
Positives
- The sales were explicitly stated as non-discretionary 'sell to cover' transactions, indicating they were for tax purposes rather than a lack of confidence in the company's future performance.
- The transfer of shares to a trust is a common estate planning activity and does not reflect negatively on the company's outlook.
Future Outlook
NA
Industry Context
This Form 4 filing details routine insider transactions for Astera Labs' CFO and does not provide information relevant to broader industry trends or competitive analysis.
Related Party Transactions
- Michael Truett Tate transferred 55,785 shares of Astera Labs Common Stock to the Tate 1997 Living Trust Dated April 24, 1997, for no consideration. The Reporting Person is a trustee of the Tate Trust.
Stakeholder Impact
- Shareholders: The 'sell to cover' transactions are routine and do not signal a change in company fundamentals. The gift to a trust is an estate planning matter and has no direct impact on other shareholders.
- Employees: No direct impact mentioned.
- Customers/Suppliers/Creditors: No direct impact mentioned.
Key Dates
| Date | Description |
|---|---|
| 1997-04-24 | Date of Tate 1997 Living Trust establishment. |
| 2025-08-18 | Date of common stock sales to cover tax withholding obligations. |
| 2025-08-19 | Date of common stock transfer to Tate Trust. |
| 2025-08-20 | Date of filing signature by Attorney-in-Fact. |
Recommendation
holdThe transactions reported are primarily non-discretionary 'sell to cover' sales for tax obligations and a gift to a trust for estate planning. These are routine insider activities and do not reflect a change in the company's operational performance or the insider's confidence in the company's future prospects. Therefore, the filing itself does not provide a basis for a change in investment recommendation.
Keywords
Astera Labs, ALAB, Form 4, Insider Trading, Stock Sale, CFO, Michael Truett Tate, Restricted Stock Units, Trust Transfer, Semiconductor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.